Advanced search
Publication Cover
Leukemia & Lymphoma Volume 51, 2010 - Issue 8
Submit an article Journal homepage
234
Views
4
CrossRef citations to date
0
Altmetric
Reviews

Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents

Kevin KellyCancer Therapy & Research Center at The University of Texas Health Science Center, Institute for Drug Development, San Antonio, TX, USA
,
Ronan SwordsCancer Therapy & Research Center at The University of Texas Health Science Center, Institute for Drug Development, San Antonio, TX, USA
,
Devalingam MahalingamCancer Therapy & Research Center at The University of Texas Health Science Center, Institute for Drug Development, San Antonio, TX, USA
&
Francis J. GilesCancer Therapy & Research Center at The University of Texas Health Science Center, Institute for Drug Development, San Antonio, TX, USACorrespondence[email protected]
Pages 1399-1413 | Received 08 Jan 2010, Accepted 29 Apr 2010, Published online: 08 Jun 2010

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Francis J Giles, Gianantonio Rosti, Photis Beris, Richard E Clark, Philipp le Coutre, Francois-Xavier Mahon, Juan-Luis Steegmann, Peter Valent & Giuseppe Saglio. (2010) Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Review of Hematology 3:6, pages 665-673.
Read now

Articles from other publishers (3)

Meng Xiao, Hongjing Zhou, Shuguo Li, Chunlei Xin, Tongfeng Zhao, Yunliang Hao, Shumei Li & Yanyan Liang. (2017) Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report. Precision Radiation Oncology 1:4, pages 134-136.
Crossref
Jane L. Liesveld. (2011) CML: Defining the efficacy of targeted therapy with the TARGET system. Leukemia Research 35:5, pages 575-576.
Crossref
Ting-Wei LuRonan SwordsFrancis J. GilesKevin Kelly. (2017) Nilotinib: A Review of its Use in Chronic Myelogenous Leukemia. Clinical Medicine Insights: Therapeutics 2, pages CMT.S24.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.